/
MIST
$1.33+$0.09 (+7.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$154.4M
124M shares
52-week range
$1.00 – $3.06
16% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.02%
Moderate
Price (6 mo)
Loading chart…
Change$-4.29
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $15.0M | $5.0M | $1.0M | $0 | $1.5M |
| Cost of revenue | $10.0K | $0 | $0 | $0 | $0 | $0 | $0 | $114.0K |
| Gross profit | −$10.0K | $0 | $0 | $15.0M | $5.0M | $1.0M | $0 | $1.4M |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% | — | 92.6% |
| R&D | $16.8M | $42.4M | $34.9M | $38.7M | $39.8M | $31.1M | $14.4M | $18.1M |
| Operating income | −$23.8M | −$57.9M | −$50.7M | −$43.1M | −$59.6M | −$61.1M | −$42.1M | −$62.5M |
| EBITDA | −$23.4M | −$57.8M | −$50.6M | −$42.8M | −$58.3M | −$57.0M | −$37.8M | −$59.5M |
| Net income | −$23.2M | −$55.2M | −$50.0M | −$42.9M | −$58.4M | −$59.7M | −$41.5M | −$63.1M |
| Net margin | — | — | — | -285.7% | -1167.8% | -5968.5% | — | -4078.8% |
| EPS (diluted) | -0.98 | -3.50 | -1.70 | -1.02 | -1.35 | -1.39 | -0.67 | -0.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-0.93 | $-1.50–$-0.71 | 4 |
| 2027 | $29M | $-1.02 | $-1.70–$-0.68 | 4 |
| 2028 | $133M | $-0.42 | $-0.57–$-0.29 | 3 |
| 2029 | $221M | $0.10 | $0.07–$0.14 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.15
Price
$1.33
Implied downside
-88%
Peer comparison
Milestone Pharmaceuticals Inc. Common Shares
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
www.milestonepharma.com- Employees
- 38
- IPO / List date
- May 9, 2019
- HQ
- MONTREAL, A8
Held by traders on TradeandTell
No one on the platform currently holds MIST.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 129,705 | $154.3K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MIST yet.
